Evidence
How we made the decision
How we made the decision
We reconsidered the previous surveillance decision for NICE's guideline on ovarian cancer following the development of the related NICE diagnostics guidance on tests in secondary care to identify people at high risk of ovarian cancer.
For details of the process and update decisions that are available, see ensuring that published guidelines are current and accurate in developing NICE guidelines: the manual.
Previous surveillance update decisions for the guideline are on our website.
Evidence
No additional evidence published since the last surveillance review in March 2016 was considered.
Views of topic experts
We considered the views of topic experts, including those who helped to develop the guideline.
Views of stakeholders
Stakeholders are consulted only if we decide not to update the guideline following checks at 4 and 8 years after publication. Because this was an exceptional surveillance review, and the decision was not to update, we did not consult on the decision.
NICE Surveillance programme project team
Kay Nolan
Associate Director
Philip Alderson
Consultant Clinical Adviser
Emma McFarlane
Technical Adviser
Patrick Langford
Technical Analyst
The NICE project team would like to thank the topic experts who participated in the surveillance process.
ISBN: 978-1-4731-0789-2
This page was last updated: